Stephane Nancey
Overview
Explore the profile of Stephane Nancey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
160
Citations
1981
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richard N, Amiot A, Seksik P, Altwegg R, Laharie D, Vuitton L, et al.
Aliment Pharmacol Ther
. 2025 Mar;
PMID: 40038887
Background: Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. Aims: This study aimed to evaluate the effectiveness and safety of upadacitinib in a real-world...
2.
Mancheron A, Dumas A, Nion Larmurier I, Landman C, Peyrin Biroulet L, Caron B, et al.
J Crohns Colitis
. 2024 Nov;
PMID: 39575831
Background And Aims: Inflammatory Bowel Disease (IBD) are known to impact patients 'sexual lives. The aim of this study is to create and validate a sexual QoL designed for youth...
3.
Laperrousaz B, Levast B, Fontaine M, Nancey S, Dechelotte P, Dore J, et al.
BMC Gastroenterol
. 2024 Nov;
24(1):402.
PMID: 39528920
Background: Multiple studies have evaluated fecal microbiota transfer (FMT) in patients with ulcerative colitis (UC) using single-donor (SDN) and multidonor (MDN) products. Systematic review and meta-analysis were performed to compare...
4.
Le Cosquer G, Kirchgesner J, Gilletta De Saint Joseph C, Seksik P, Amiot A, Laharie D, et al.
Clin Gastroenterol Hepatol
. 2024 Nov;
PMID: 39505240
Background & Aims: Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence...
5.
Reenaers C, Enea D, Nachury M, Laharie D, Bouhnik Y, Fumery M, et al.
J Crohns Colitis
. 2024 Nov;
PMID: 39487737
Background And Aims: Achieving deep remission, encompassing clinical, endoscopic, and biological remission, is the goal in managing Crohn's disease (CD). The role of histological remission remains unclear. This study aimed...
6.
Laharie D, Bouhnik Y, Vuitton L, Biron A, Pierron G, Brault Y, et al.
Clin Res Hepatol Gastroenterol
. 2024 Oct;
48(10):102483.
PMID: 39448029
Background: ReFLECT was a French, prospective, multicenter, observational cohort study evaluating the effectiveness and safety of the infliximab (IFX) biosimilar CT-P13 in a real-world setting. Here, we describe the results...
7.
Goren I, Fallek Boldes O, Boldes T, Knyazev O, Kagramanova A, Limdi J, et al.
J Crohns Colitis
. 2024 Oct;
PMID: 39435855
Objectives: Elderly hospitalized patients with inflammatory bowel disease (IBD) flare and concurrent Clostridioides difficile infection (CDI) are considered at high risk of IBD-related complications. We aimed to evaluate the short,...
8.
Roblin X, Little R, Mathieu N, Paul S, Nancey S, Barrau M, et al.
Expert Rev Gastroenterol Hepatol
. 2024 Oct;
18(10):575-586.
PMID: 39382556
Introduction: Therapeutic Drug Monitoring (TDM) has an important role in the management of inflammatory bowel disease (IBD) patients on infliximab (IFX) or adalimumab and is recommended in IBD patients presenting...
9.
Alonso-Gomez M, Charlois A, Cotte E, Gay C, Danion P, Malezieux E, et al.
Clin Res Hepatol Gastroenterol
. 2024 Sep;
48(9):102473.
PMID: 39349101
Background: Real life data about the long-term efficacy of darvadstrocel for treating perianal fistulas in Crohn's disease (CD) remain scarce. Aim: To report the effectiveness and safety of darvadstrocel therapy...
10.
Bouguen G, Gossec L, Abitbol V, Senbel E, Bonnaud G, Roblin X, et al.
BioDrugs
. 2024 Sep;
38(6):867-878.
PMID: 39322802
Background And Objectives: Biosimilars are cost-effective alternatives to reference products for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs can affect adherence to...